Clinical Trials for Cervical Cancer

Study of Intratumoral Injections of VLPONC-01 in Head and Neck Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with head and neck squamous cell carcinoma eligible for intratumoral injection: either unresectable/recurrent/metastatic disease post–PD-1/PD-L1 and standard therapies (IT VLPONC-01 alone) or resectable stage I–IVb disease planned for surgery (neoadjuvant pembrolizumab with or without IT VLPONC-01). VLPONC-01 is a virus replicon particle–delivered self-amplifying RNA encoding IL-12 to drive local innate/adaptive immune activation and potentially sensitize tumors to PD-1 blockade.

ClinicalTrials.gov ID: NCT06736379

Pilot Phase II Study to Evaluate Effect of Cetuximab Given as Single Agent After Immunotherapy With PD-1 Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent/metastatic HNSCC who have progressed on or were intolerant to prior PD‑1–based therapy receive single‑agent cetuximab (weekly IV), an anti‑EGFR monoclonal antibody that blocks ligand-induced signaling and mediates ADCC. Single-arm study assessing response rate, with secondary PFS/OS and safety.

ClinicalTrials.gov ID: NCT04375384

Alternating Treatment Plans for Participants With Advanced Thoracic/Head & Neck Cancers (ATATcH)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with untreated metastatic NSCLC (squamous or nonsquamous without targetable drivers) or incurable recurrent/metastatic HNSCC eligible for pembrolizumab-based first line receive an alternating induction schedule of chemoimmunotherapy cycles interspersed with pembrolizumab monotherapy. Regimens use standard backbones (carboplatin/paclitaxel or nab-paclitaxel for squamous NSCLC; carboplatin/pemetrexed with optional pemetrexed maintenance for nonsquamous NSCLC; carboplatin/5-FU for HNSCC) plus pembrolizumab, an anti–PD-1 antibody.

ClinicalTrials.gov ID: NCT05358548

A Prospective Cohort Study of Integrating Radiotherapy Into Chemotherapy With Pembrolizumab and Bevacizumab in Newly Diagnosed Stage IVB Cervical Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with newly diagnosed, untreated stage IVB, PD-L1–positive cervical cancer (squamous/adenocarcinoma/adenosquamous), ECOG 0–1, receive induction cisplatin/paclitaxel plus pembrolizumab (anti–PD-1) and bevacizumab (anti-VEGF), followed by definitive pelvic EBRT with brachytherapy while continuing pembrolizumab/bevacizumab. Designed to assess safety and efficacy of adding definitive radiotherapy to the current chemoimmunotherapy/bevacizumab backbone; excludes prior systemic therapy/RT or checkpoint inhibitors and active autoimmune disease.

ClinicalTrials.gov ID: NCT06543576

Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with iodine‑avid but RAI‑insufficient papillary/follicular DTC with unresectable locoregional invasion and/or distant metastases receive individualized combination therapy of systemic I‑131 and external beam radiotherapy, using integrated dosimetry to escalate cumulative dose (target ≥80 Gy) to selected lesions. Aims to assess safety and preliminary efficacy with coordinated RAI+XRT planning in patients with adequate organ function and no contraindications to TSH stimulation or radiation.

ClinicalTrials.gov ID: NCT04892303

Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic NSCLC (EGFR/ALK–, PD-L1 TPS ≥50%), HNSCC (PD-L1 CPS ≥20), or melanoma (any PD-L1/BRAF) who are either ICI-naive or have progressed on prior PD‑1/PD‑L1 therapy receive pembrolizumab plus CJRB‑101, an oral live biotherapeutic (Leuconostoc mesenteroides) designed to modulate the tumor-immune microenvironment (macrophage repolarization, APC activation, ↑CD8+ infiltration) to enhance PD‑1 blockade. Key exclusions include EGFR/ALK+ NSCLC, nasopharyngeal carcinoma, uncontrolled brain mets, significant autoimmune disease/IBD, key infections, and inability to take oral capsules.

ClinicalTrials.gov ID: NCT05877430

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable, recurrent, or metastatic androgen receptor–positive salivary gland carcinoma (ECOG 0–1), including previously treated patients without prior ADT or checkpoint inhibitors, receive goserelin (GnRH agonist ADT) plus pembrolizumab (anti–PD-1) until progression or toxicity. Stable, treated brain metastases are allowed; key exclusions include active autoimmune disease requiring systemic therapy and significant immunosuppression.

ClinicalTrials.gov ID: NCT03942653

A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent/metastatic HNSCC (oropharynx, oral cavity, hypopharynx, or larynx) receive subcutaneous amivantamab—an EGFR/MET bispecific antibody—either as monotherapy or combined with pembrolizumab, paclitaxel, or pembrolizumab plus carboplatin, with cohort-specific HPV/p16 requirements and prior therapy allowances. The study assesses safety and antitumor activity across these regimens and establishes the recommended dose for the amivantamab-paclitaxel combination.

ClinicalTrials.gov ID: NCT06385080

Administration of T Cells Expressing Chondroitin-Sulfate-Proteoglycan-4 Specific Chimeric Antigen Receptors (CAR) in Subjects With Head and Neck Squamous Cell Carcinoma (HNSCC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated recurrent/metastatic HNSCC (oral cavity, oropharynx, hypopharynx, larynx; KPS >60%) receive lymphodepleting cyclophosphamide/fludarabine followed by a single infusion of autologous iC9.CAR-CSPG4 T cells, an anti-CSPG4 CAR T product with an inducible caspase-9 safety switch for potential rapid ablation. Key exclusions include significant cardiovascular disease, recent stroke/TIA, and severe hypersensitivity to cyclophosphamide or fludarabine.

ClinicalTrials.gov ID: NCT06096038

An Open Label Phase II Trial Evaluating the Efficacy of Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic, RAI‑refractory differentiated thyroid cancer with RECIST-defined progression (ECOG 0–2) receive oral cyclophosphamide (intermittent low-dose) plus sirolimus daily. Sirolimus targets mTORC1 (PI3K/AKT/mTOR pathway inhibition), aiming for antiproliferative/antiangiogenic synergy with metronomic cyclophosphamide; excludes prior mTOR inhibitor exposure and requires available prior NGS.

ClinicalTrials.gov ID: NCT03099356